Home > Boards > US Listed > Medical - Drugs > Sol Gel Technologies Ltd (SLGL)

Re: BVXV

Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
midastouch017 Member Profile
 
Followed By 120
Posts 25,368
Boards Moderated 8
Alias Born 02/07/04
160x600 placeholder
Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k) Edgar (US Regulatory) - 3/22/2021 1:25:07 PM
Raymond James: These 3 Stocks Are Poised to Surge by at Least 50% TipRanks - 3/10/2021 10:29:53 AM
Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k) Edgar (US Regulatory) - 3/9/2021 1:07:46 PM
Sol-Gel Technologies reports FY 2020 results Seeking Alpha - 3/4/2021 7:55:57 AM
Annual and Transition Report (foreign Private Issuer) (20-f) Edgar (US Regulatory) - 3/4/2021 7:43:55 AM
Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k) Edgar (US Regulatory) - 3/4/2021 7:38:05 AM
Sol-Gel Technologies Reports Full Year 2020 Financial Results and Corporate Update GlobeNewswire Inc. - 3/4/2021 7:05:00 AM
Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k) Edgar (US Regulatory) - 3/1/2021 6:32:50 AM
Sol-Gel Technologies to Present at Upcoming 2021 Raymond James Institutional Investors Conference and H.C. Wainwright Global ... GlobeNewswire Inc. - 2/24/2021 7:05:00 AM
Amended Statement of Ownership (sc 13g/a) Edgar (US Regulatory) - 2/11/2021 11:13:48 AM
Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k) Edgar (US Regulatory) - 2/5/2021 6:06:42 AM
Sol-Gel Technologies to Present at Upcoming 2021 Solebury Trout Virtual Investor Conference and H.C. Wainwright BioConnect Co... GlobeNewswire Inc. - 1/11/2021 7:05:00 AM
Sol-Gel Technologies Announces FDA Acceptance for Filing of New Drug Application for Twyneo® for the Treatment of Acne Vulga... GlobeNewswire Inc. - 12/7/2020 7:05:00 AM
Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k) Edgar (US Regulatory) - 11/12/2020 9:12:06 AM
Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k) Edgar (US Regulatory) - 11/12/2020 9:08:36 AM
Sol-Gel Technologies Reports Third Quarter 2020 Financial Results and Corporate Update GlobeNewswire Inc. - 11/12/2020 7:05:00 AM
Sol-Gel to Present at Upcoming Healthcare Investor Conferences in November 2020 GlobeNewswire Inc. - 11/9/2020 7:05:00 AM
Sol-Gel Technologies to Report Third Quarter 2020 Financial Results on November 12, 2020 GlobeNewswire Inc. - 11/4/2020 4:05:00 PM
Report of Foreign Issuer (6-k) Edgar (US Regulatory) - 9/14/2020 9:14:10 AM
Sol-Gel Technologies Announces FDA Acceptance for Filing of New Drug Application for Epsolay® for the Treatment of Inflammat... GlobeNewswire Inc. - 9/10/2020 4:01:10 PM
Sol-Gel to Present at Upcoming Healthcare Investor Conferences in September GlobeNewswire Inc. - 9/8/2020 7:05:10 AM
Report of Foreign Issuer (6-k) Edgar (US Regulatory) - 9/3/2020 8:41:29 AM
Sol-Gel Technologies Collaboration Partner Filed First-to-File Paragraph IV Certification for Duobrii® GlobeNewswire Inc. - 9/3/2020 7:05:10 AM
Report of Foreign Issuer (6-k) Edgar (US Regulatory) - 8/6/2020 10:40:18 AM
Report of Foreign Issuer (6-k) Edgar (US Regulatory) - 8/6/2020 10:37:55 AM
midastouch017   Friday, 04/17/20 06:57:34 AM
Re: Amatuer17 post# 13
Post # of 36 
Re: BVXV

Quote:
good news is trial is over and results
will by end of the year.



Another earlier indication might come soon:

JERUSALEM, Feb. 5, 2020 /PRNewswire/ -- BiondVax Pharmaceuticals Ltd. (Nasdaq: BVXV) announced today that preliminary data from the Phase 2 clinical trial of BiondVax's M-001 universal influenza vaccine candidate have been published. The trial was supported by the U.S. National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH). The primary objectives of the trial were to assess safety and T-cell responses to M-001. The data, which are consistent with results of previous clinical trials of M-001, indicate that both primary objectives were achieved. Analysis of the data is ongoing, and the clinical study report (CSR) is expected in Q2 2020.

https://www.prnewswire.com/il/news-releases/preliminary-data-from-nihniaid-sponsored-phase-2-clinical-trial-of-biondvaxs-m-001-universal-influenza-vaccine-candidate-validates-results-of-previous-clinical-trials-300999644.html

Anyway, $6 entry point would be very attractive!

smile

Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist
Consent Preferences